The financing will be used to expand technical teams and accelerate the commercialisation of its proteomics platform.
"Portal Biotech’s technology offers unprecedented capabilities in protein identification and characterisation, providing unmatched detail on protein structure and modifications at the single-molecule level on accessible desktop instruments that bring this state-of-the-art characterisation to any lab. These powerful advances are essential for accelerating drug discovery and enhancing diagnostic precision, positioning Portal Biotech as the frontrunner in the race to unlock the full potential of protein sequencing."
The seed round was co-led by Octopus Ventures and redalpine to support preclinical candidate selection and pipeline development.
"At ExpressionEdits, we’re revolutionizing gene expression by putting introns back where they belong, resulting in significant improvements in production"
Creandum led the Series A round with participation from Peter Thiel, firstminute, Seedcamp, Hambro Perks and Amino Collective.
"Clinical trials are the biggest bottleneck to improving human health. We deliver clinical trials three times faster than the industry standard, working with biotech pioneers to get new treatments to patients more quickly."
The seed round was backed by investors including Firstminute Capital, Presight Capital, and Seedcamp.
"Traditional clinical research companies are dinosaurs. Taking part in a COVID vaccine trial was like stepping into a time machine. This was one of the best funded trials in history but research was done on pen and paper and participants had to go into hospital at the height of the pandemic to fill out forms. We founded Lindus Health to make it easier for patients to participate in research, and accelerate the development of new treatments."
-20webclip.png)
